Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity

Effects of GIP receptor-modulating compounds on different tissues have implications for both weight reduction and other cardiometabolic diseases. Further study is needed to understand the implications of GIP agonism on not just weight reduction, but also cardiovascular disease, liver disease, bone health and fat storage.